GENEDX HOLDINGS CORP
WGSNASDAQTrading Snapshot
- Day Range
- $76.11 – $78.25
- 52-Week Range
- $32.21 – $170.87
- Volume
- $5.26B
- Avg Volume
- $5.23B
- Shares Outstanding
- 29.8M
- Next Earnings
- Oct 23, 2026
Fundamentals Snapshot
- Annual Revenue
- $428M
- Last Q Revenue
- $114M
- P/E Ratio
- -23.6
- P/S Ratio
- 5.6x
- EPS (TTM)
- $-3.58
- Dividend Yield
- 0.00%
- Dilution (1yr)
- −0.4%
Why Investors Own WGS
- ✓High-growth profile — revenue up -1.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 64% gross margin and 11% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
GENEDX HOLDINGS CORP
WGS
StockOtter · stockotter.spaceAbout GENEDX HOLDINGS CORP
GeneDx Holdings Corp. functions as a health intelligence firm singularly focused on the individual patient. It aims to revolutionize healthcare delivery by deploying advanced artificial intelligence and machine learning capabilities. These sophisticated algorithms are applied to vast, longitudinal clinical and genomic datasets to construct comprehensive, dynamic models of human health, ultimately defining personalized, optimal pathways for each person's well-being. Through its exclusive Centrellis health intelligence platform, the company gains profound insights into both disease states and overall wellness, enabling it to furnish evidence-based solutions for the most critical medical challenges. Eric Schadt established the corporation in October 2015, and its principal offices are located in Stamford, Connecticut.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Kevin Feeley Sells 3,728 Shares of GeneDx (NASDAQ:WGS) Stock
GeneDx Holdings Corp. (NASDAQ: WGS - Get Free Report) CFO Kevin Feeley sold 3,728 shares of GeneDx stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $97.61, fo
Tempus Launches Effort to Build the Largest Multimodal Whole-Genome Dataset to Advance AI-Driven Healthcare Innovation
Tempus AI, Inc. (NASDAQ: TEM) today announced an initiative to build a research platform containing 100,000 whole genomes linked to longitudinal clinical inform
GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C.
3 Promising Genomics Stocks in the Spotlight in 2026
Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicine.
GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree
GAITHERSBURG, Md.--(BUSINESS WIRE)--Katherine Stueland, CEO of GeneDx, has been named a 2026 Fierce 50 honoree for Health Equity.
GeneDx Holdings Corp (WGS) Shares Surge 3.3% -- What GF Score of 65 Tells Investors
On August 26, 2026, GeneDx Holdings Corp (WGS) shares rose 3.3%, bringing the current price to $90.28. The stock is trading within a 52-week range of $32.21 to